Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cybin Inc. (CYBN.NE)
Toronto, ON, CA
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.46% | -5.45% | -13.33% | -37.91% | -28.36% | -43.83% | -42.80% | -55.62% | -90.40% | -82.53% | -82.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-863.9% Q1'26: +36.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%-189.5% Q1'26: -252.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-81.2% ★ Q1'26: +137.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2025 actual |
Mar 2026 2 EPS Ana. |
Mar 2027 5 Rev. Ana. 4 EPS Ana. |
Mar 2028 1 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
864.0K
est: 588.0K (+46.9%)
|
—
|
—
— – —
|
10.97M
10.97M – 10.97M
|
29.92M
29.92M – 29.92M
+172.8% YoY
|
534.41M
534.41M – 534.41M
+1,685.9% YoY
|
1.15B
1.15B – 1.15B
+115.5% YoY
|
| EBITDA |
-32.16M
est: 352.8K (-9,215.9%)
|
-142.67M
|
—
— – —
|
6.58M
6.58M – 6.58M
|
17.95M
17.95M – 17.95M
+172.8% YoY
|
320.64M
320.64M – 320.64M
+1,685.9% YoY
|
691.05M
691.05M – 691.05M
+115.5% YoY
|
| EBIT |
-32.22M
est: 352.8K (-9,232.7%)
|
-143.15M
|
—
— – —
|
6.58M
6.58M – 6.58M
|
17.95M
17.95M – 17.95M
+172.8% YoY
|
320.64M
320.64M – 320.64M
+1,685.9% YoY
|
691.05M
691.05M – 691.05M
+115.5% YoY
|
| Net Income |
-32.22M
est: -1.67B (+98.1%)
|
-113.14M
est: -935.49M (+87.9%)
|
-150.02M
-160.22M – -139.82M
+84.0% YoY
|
-113.70M
-156.53M – -77.05M
+24.2% YoY
|
-114.96M
-114.96M – -114.96M
-1.1% YoY
|
-7.58M
-7.58M – -7.58M
+93.4% YoY
|
110.78M
110.78M – 110.78M
+1,561.8% YoY
|
| SGA |
27.42M
est: 4.08M (+572.2%)
|
88.24M
|
—
— – —
|
78.41M
78.41M – 78.41M
|
213.90M
213.90M – 213.90M
+172.8% YoY
|
3.82B
3.82B – 3.82B
+1,685.9% YoY
|
8.23B
8.23B – 8.23B
+115.5% YoY
|
| EPS |
-12.16
est: -8.99 (-35.2%)
|
-0.61
est: -5.05 (+87.9%)
|
-4.31
-4.60 – -4.02
+14.6% YoY
|
-3.27
-4.50 – -2.21
+24.2% YoY
|
-3.30
-3.30 – -3.30
-1.1% YoY
|
-0.22
-0.22 – -0.22
+93.4% YoY
|
3.18
3.18 – 3.18
+1,561.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul Glavine | Co-Founder, Chief Growth Officer & Director | 976.6K | male |
| Eric So | Co-Founder, Interim Chief Executive Officer, President & Executive Chairman | 976.6K | male |
| John Kanakis | Co-Founder | 957.4K | male |
| Gabriel Fahel | Chief Legal Officer & Corporate Secretary | 712.1K | male |
| George Tziras | Chief Business Officer | 693.3K | male |
| Greg Cavers | Chief Financial Officer | 678.2K | male |
| Aaron Bartlone | Chief Operating Officer | 619.9K | male |
| Lori Challenger | Chief Compliance, Ethics & Administrative Officer | — | female |
| Alex L. Nivorozhkin | Chief Scientific Officer | — | — |
| Sara Brittany Somerset | Chief Communications Officers | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CYBN.NE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
